Welcome to our dedicated page for Maxcyte SEC filings (Ticker: MXCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MaxCyte, Inc. (NASDAQ: MXCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol MXCT, MaxCyte uses SEC reports to communicate material events, financial results, capital market actions and governance changes related to its cell-engineering business.
Investors researching MXCT can use this page to review Form 8-K filings that describe significant developments. Recent 8-Ks have covered preliminary unaudited financial results, quarterly earnings releases, an operational restructuring and workforce reduction plan, and leadership changes such as the departure of the chief commercial officer. Another 8-K details MaxCyte’s application to cancel admission of its common stock to trading on the AIM market of the London Stock Exchange, while confirming that its Nasdaq listing remains in place.
MaxCyte’s SEC filings also reference its use of non-GAAP financial measures, including EBITDA, Adjusted EBITDA and Non-GAAP Gross Margin, and explain how management uses these metrics alongside GAAP results. Filings describe the company’s revenue composition, distinguishing between core business revenue and Strategic Platform License (SPL) program-related revenue, and discuss expectations for cost structure and cash resources.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as restructuring costs, expected annualized savings, revenue guidance and capital position. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs and 10-Ks appear promptly, while insider-related disclosures on forms such as Form 4 can be accessed to track reportable transactions by directors and officers. This combination of original filings and AI-generated insights offers a structured way to analyze MaxCyte’s regulatory history and ongoing reporting.
MaxCyte, Inc. is asking stockholders to elect three Class II directors—Patrick Balthrop, Cynthia Collins, and Stanley Erck—to serve until the 2029 annual meeting, and to ratify CohnReznick LLP as independent auditor for the year ending December 31, 2026.
The 2026 annual meeting will be held on June 17, 2026 at 11:00 a.m. Eastern Time in Rockville, Maryland, for holders of 107,121,672 common shares outstanding as of April 21, 2026. The board reports that eight of nine directors are Nasdaq‑independent and is led by an independent non‑executive chair, Richard Douglas.
For 2025, CEO Maher Masoud received total compensation of $2,687,657, including salary, equity awards, and an annual bonus funded at 88.5% of target, based on goals tied to revenue, EBITDA and operational milestones. Major stockholders include Capricorn Fund Managers (7.7%), BlackRock (6.5%), and River Global Investors (5.1%).
Ahuja Parmeet reported acquisition or exercise transactions in this Form 4 filing.
MAXCYTE, INC. Chief Financial Officer Parmeet Ahuja reported an equity award of 187,500 shares of Common Stock in the form of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of common stock at no purchase price.
According to the filing, 25% of the RSUs will vest on March 30, 2027, and the remaining RSUs will vest in three equal annual installments after that date, subject to Ahuja’s continued service with the company through each vesting date. Following this grant, Ahuja directly holds 187,500 shares reported in this Form 4.
MAXCYTE, INC. Chief Financial Officer Parmeet Ahuja received a grant of employee stock options covering 375,000 shares of Common Stock. The options have an exercise price of $0.6762 per share and expire on March 29, 2036.
According to the vesting schedule, 25% of the shares underlying this option vest on March 30, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, contingent on continued service. Following this grant, Ahuja holds 375,000 stock options directly.
MAXCYTE, INC. filed an initial insider ownership report for Parmeet Ahuja, who serves as Chief Financial Officer. This Form 3 establishes Ahuja as a reporting person for future disclosures of any holdings or transactions in MAXCYTE, INC. securities, but does not itself report any transactions or share ownership changes.
Mirabella Financial Services LLP notifies MaxCyte that it holds 0 shares of Common Stock and no longer acts as the investment manager for Blue Riband Fund LP. The filing states Mirabella ceased manager discretion on 5 January 2026 and the certification was signed on 04/10/2026.
MAXCYTE, INC. President and CEO Masoud Maher received an equity compensation package consisting of stock options and restricted stock units. He was granted an option to buy 600,000 shares of common stock at an exercise price of $0.684 per share, expiring on March 26, 2036. Twenty-five percent of these option shares vest on March 27, 2027, with the rest vesting in 36 equal monthly installments, as long as he continues serving the company. He also received 300,000 restricted stock units, each representing one share of common stock. Twenty-five percent of the RSUs vest on March 27, 2027, and the remaining units vest in three equal annual installments, again contingent on continued service. Following the RSU grant, he holds 475,000 common shares directly. These are compensation-related awards, not open-market purchases or sales.
MaxCyte, Inc. has appointed Parmeet Ahuja as Chief Financial Officer and principal accounting officer, effective March 30, 2026, succeeding Douglas Swirsky following a previously announced transition. Ahuja brings over 20 years of finance leadership experience from Agilent Technologies, including roles in investor relations, FP&A, operations and global financial operations.
Ahuja will receive an annual base salary of $450,000, with a target annual cash bonus equal to 50% of base salary. As an inducement to join, he will be granted a nonqualified stock option for 375,000 shares of common stock and a restricted stock unit award covering 187,500 shares. A severance agreement is expected, providing salary continuation, bonus, COBRA coverage and equity vesting acceleration if he is terminated without cause or resigns for good reason, with enhanced benefits in connection with a change of control.
The Vanguard Group amended a Schedule 13G to report zero beneficial ownership of MaxCyte Inc. common stock. The amendment explains an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries/divisions to report holdings separately. The filing states 0 shares (0%) beneficially owned and is signed March 27, 2026.
MaxCyte, Inc. is a commercial cell engineering company whose ExPERT Flow Electroporation platform underpins next-generation cell and gene therapy research, clinical development and manufacturing. The product family spans five instruments plus proprietary processing assemblies, consumables and GMP electroporation buffer, with more than 857 instruments installed globally.
The company focuses on Strategic Platform Licenses, or SPLs, that pair annual instrument fees with potential precommercial milestones and commercial sales-based payments. MaxCyte reports 33 SPL agreements, 31 active, with 13 clinical programs as of December 31, 2025. These SPLs have potential to generate more than $2 billion, including over $130 million in precommercial milestone opportunities from active clinical programs, of which more than $30 million has been realized so far.
In January 2025, MaxCyte acquired SeQure Dx, adding on- and off-target gene-editing assessment assays and services to support ex vivo and in vivo therapy developers. The company remains loss-making, with a 2025 net loss of $44.6 million and an accumulated deficit of $261.5 million as of December 31, 2025. Research and development expenses were $20.8 million in 2025 and $22.2 million in 2024, reflecting continued investment in platform innovation. Management highlights dependence on biopharmaceutical R&D spending, milestone timing under SPLs, competition from other non-viral delivery and electroporation providers, and regulatory and data-privacy obligations as key risks.